EyePoint Pharmaceuticals’ (EYPT) “Buy” Rating Reiterated at Chardan Capital

EyePoint Pharmaceuticals (NASDAQ:EYPT)‘s stock had its “buy” rating reiterated by Chardan Capital in a research note issued on Thursday,Benzinga reports. They presently have a $33.00 target price on the stock. Chardan Capital’s price target would indicate a potential upside of 323.08% from the company’s previous close.

EYPT has been the topic of a number of other reports. Scotiabank assumed coverage on EyePoint Pharmaceuticals in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $18.00 target price on the stock. Citigroup assumed coverage on shares of EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating and a $33.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $22.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, December 5th. Finally, Robert W. Baird lowered their price target on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating on the stock in a research report on Monday, November 11th. One research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $26.63.

EyePoint Pharmaceuticals Trading Up 2.4 %

Shares of EYPT opened at $7.80 on Thursday. EyePoint Pharmaceuticals has a twelve month low of $6.55 and a twelve month high of $30.99. The firm has a market capitalization of $532.35 million, a PE ratio of -3.90 and a beta of 1.51. The stock’s 50 day moving average is $7.97 and its two-hundred day moving average is $8.84.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.06). The company had revenue of $10.52 million for the quarter, compared to analyst estimates of $12.35 million. EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. On average, sell-side analysts predict that EyePoint Pharmaceuticals will post -2.13 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of EYPT. Levin Capital Strategies L.P. increased its stake in shares of EyePoint Pharmaceuticals by 440.0% during the 4th quarter. Levin Capital Strategies L.P. now owns 54,000 shares of the company’s stock valued at $402,000 after acquiring an additional 44,000 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in EyePoint Pharmaceuticals by 22.2% in the fourth quarter. Bank of New York Mellon Corp now owns 204,260 shares of the company’s stock valued at $1,522,000 after purchasing an additional 37,054 shares during the period. Rhumbline Advisers increased its position in EyePoint Pharmaceuticals by 16.1% during the fourth quarter. Rhumbline Advisers now owns 89,560 shares of the company’s stock worth $667,000 after purchasing an additional 12,443 shares during the last quarter. Deltec Asset Management LLC purchased a new position in EyePoint Pharmaceuticals during the fourth quarter worth approximately $151,000. Finally, abrdn plc acquired a new position in shares of EyePoint Pharmaceuticals in the 4th quarter valued at $1,719,000. 99.41% of the stock is currently owned by institutional investors and hedge funds.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.